IDEAS home Printed from https://ideas.repec.org/a/spr/pharme/v34y2016i6d10.1007_s40273-016-0382-3.html
   My bibliography  Save this article

Apremilast for the Treatment of Moderate to Severe Plaque Psoriasis: A Critique of the Evidence

Author

Listed:
  • Sebastian Hinde

    (University of York)

  • Ros Wade

    (University of York)

  • Stephen Palmer

    (University of York)

  • Nerys Woolacott

    (University of York)

  • Eldon Spackman

    (University of York)

Abstract

As part of the National Institute for Health and Care Excellence’s (NICE) single technology appraisal (STA) process, apremilast was assessed to determine the clinical and cost effectiveness of its use in the treatment of moderate to severe plaque psoriasis in two patient populations, differentiated by the severity of the patient’s Psoriasis Area Severity Index (PASI) score. The Centre for Reviews and Dissemination (CRD) and the Centre for Health Economics (CHE) Technology Appraisal Group at the University of York was commissioned to act as the evidence review group (ERG). This article provides a summary of the company’s submission, the ERG report and NICE’s subsequent guidance. In the company’s initial submission, a sequence of treatments including apremilast was found to be both more effective and cheaper than a comparator sequence without it in both populations considered. However, this result was found to be highly sensitive to a series of assumptions made by the company, primarily reflecting the costs of best supportive care once no further treatments are available, and the source of utility estimates. A re-estimation of the cost effectiveness of apremilast by the ERG suggested that the apremilast sequence in the two populations was more effective, but due to high additional costs was not indicative of a cost-effective use of NHS resources. As such, in the final appraisal decision NICE concluded that apremilast was not cost effective in either population.

Suggested Citation

  • Sebastian Hinde & Ros Wade & Stephen Palmer & Nerys Woolacott & Eldon Spackman, 2016. "Apremilast for the Treatment of Moderate to Severe Plaque Psoriasis: A Critique of the Evidence," PharmacoEconomics, Springer, vol. 34(6), pages 587-596, June.
  • Handle: RePEc:spr:pharme:v:34:y:2016:i:6:d:10.1007_s40273-016-0382-3
    DOI: 10.1007/s40273-016-0382-3
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40273-016-0382-3
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.

    File URL: https://libkey.io/10.1007/s40273-016-0382-3?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:34:y:2016:i:6:d:10.1007_s40273-016-0382-3. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.